Skip to main content

Advertisement

Upregulated TCRζ improves cytokine secretion in T cells from patients with AML

Article metrics

Abstract

Previous studies indicated that upregulating TCRζ partially recovers T cell function in patients with leukemia. In this study, we characterized the cytokine profile of TCRζ-transfected T cells from acute myeloid leukemia (AML) patients by Quantibody®Array Glass Chip. Firstly, the significantly lower expression of TCRζ in CD3+/TCRζ+ cells from AML patients was found. Increased secretion of IL-2, IL-8, IL-10, IL-13, IFN-γ, TNF-α, GM-CSF, growth-regulated oncogene (GRO), MIP-1b, and regulated on activation, normal T cell expressed and secreted (RANTES) could be detected in T cells from AML patients after TCRζ upregulating. We concluded that upregulating TCRζ in T cells from AML can alter the secretion profile of cytokines and chemokine which are involved in T cell proliferation and activation.

Findings

Acute myeloid leukemia (AML) is an aggressive disease with an unfavorable prognosis [13]. T cell immunodeficiency is a common characteristic in hematological malignancies which may be due to defective TCRζ. Previous studies showed that TCRζupregulation could be induced in CD3+T cells from AML patients by IL-2, IL-7, and IL-12 [4]. In this study, we characterized the secretion profile of cytokines and chemokines related to T cell activation in TCRζ-IRES2-EGFP-transfected T cells from AML patients after TCRζupregulation.

First, significantly lower TCRζ expression in CD3+/TCRζ+ cells in AML (2.89 ± 2.6 %, n = 10) was found in comparison with healthy individuals (87.38 ± 15.67 %, n = 10) (p < 0.001) (Fig. 1a–c). This result further supported our previous finding that T cell immunodeficiency might be due to low TCRζ signaling in T cells [58].

Fig. 1
figure1

Expression of CD3+/TCRζ+ cells in PBMCs and expression of TCRζ and Zap-70 in TCRζ-transfected CD3+ T cells from patients with AML. a MFI of CD3+/TCRζ+ in PBMCs from AML patients and healthy individuals (HI) (n =10). b Percentage of CD3+/TCRζ+ cells in PBMCs from a healthy individual. c Percentage of CD3+/TCRζ+ in PBMCs from a patient with AML. d TCRζ gene expression levels. e Zap-70 gene expression level in TCRζ-transfected CD3+ T cells and control cells. f TCRζ and Zap-70 protein expression in transfected CD3+ T cells from two AML samples and control cells

CD3+T cells were sorted from PBMCs from four AML patients (Additional file 1: Table S1) who had TCRζ deficiency and then transfected with TCRζ-IRES2-EGFP or IRES2-EGFP, respectively, by nucleofection [9]. Significant upregulation of TCRζ in TCRζ-IRES2-EGFP-transfected CD3+T cells was confirmed. Similar results were found in TCRζ downstream target factor Zap-70 (Fig. 1d–f). Thus, TCRζ gene transfection could directly upregulate TCRζ and Zap-70 in T cells from AML patients as previously found in CML [9].

Forced TCRζ chain expression can reverse TCR/CD3-mediated signaling abnormalities and defective IL-2 production in T cells [9, 10]. In this study, we used Quantibody®Array Glass Chip (www.raybiotech.com) to quantitatively measure 20 human cytokines and chemokines in supernatants from TCRζ-IRES2-EGFP-transfected and IRES2-EGFP-transfected T cells from AML patients (Additional file 2). Increased secretion of IL-2, IL-8, IL-10, IL-13, IFN-γ, TNF-α, GM-CSF, growth-regulated oncogene (GRO), MIP-1b, and regulated on activation, normal T cell expressed and secreted (RANTES) and decreased secretion of IL-5 were found, while the secretion level of IL-1α, IL-1β, IL-4, IL-6, and IL-12 had no obvious change after TCRζupregulation. Moreover, the changes in the secretion levels of IL-10, MCP-1, MIP-1a, MMP-1, and VEGF were different in different AML samples (Fig. 2). After TCRζ transfection, the IFN-γ secretion level was increased in all samples in the TCRζ-IRES2-EGFP group (median 71.46 pg/mL) compared with the pIRES2-EGFP group (median 42 pg/mL) (P = 0.253) because the basal level of IFN-γ in T cells from different AML patients was relatively different, ranging from 18.89 to 169.41 pg/mL in control cells and from 54.02 to 335.33 pg/mL in TCRζ-IRES2-EGFP cells. Thus, it could be understood that the increased secretion of IFN-γ was not statistically different in this study even though there was an obvious change in its level. Similar characteristic was found in TNF-α secretion level (Additional file 3: Figure S1). Interestingly, we found that the level of GM-CSF was significantly increased (21.63 ± 15.19 pg/mL for TCRζ-IRES2-EGFP cells vs. 1.96 ± 1.83 pg/mL for pIRES2-EGFP cells) (p = 0.045) (Fig. 2), and IL-13, which is secreted by activated T cells and has synergistic effects with GM-CSF and G-CSF, was also upregulated after TCRζ gene transfection (Fig. 2). Recently, increasing data have shown that GM-CSF has a variety of effects on the immune system including the activation of T cells, maturation of dendritic cells, and the ability to promote humoral and cell-mediated responses; thus, it has been incorporated into immunotherapy strategies [11, 12].

Fig. 2
figure2

Detection of the IL-2, IL-5, IL-8, IL-10, IL-13, RANTES, GM-CSF, MIP-1b, IFN-γ, and TNF-α level secreted from T cells from AML patients using Quantibody® array. a Fluorescence intensity (concentration) from laser scanner results. 1–4: four parallel wells for each sample. b The level of IL-2, IL-5, IL-8, IL-10, IL-13, RANTES, GM-CSF, and MIP-1b secreted from T cells from four cases with AML

In conclusion, we characterized the profile of cytokines and chemokines secretion in T cells after TCRζ gene transfection. Most cytokines related to T cell proliferation and activation, such as IL-2, IFN-γ, and TNF-α, had increased secretion after TCRζ upregulating. Moreover, some of the Th1-associated CC subfamily chemokines, such as CCL4 and CCL5, may contribute to T cell activation via TCRζ upregulation. These results may further support the idea of the effects of upregulating TCRζ in T cell immunity.

References

  1. 1.

    Löwenberg B. Prognostic factors in acute myeloid leukaemia. Best Pract Res ClinHaematol. 2001;14:65–75.

  2. 2.

    Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, et al. Azacitidine in patients with WHO-defined AML—results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J HematolOncol. 2013;6:32.

  3. 3.

    van der Helm LH, Scheepers ER, Veeger NJ, Daenen SM, Mulder AB, van den Berg E, et al. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol. 2013;6:29.

  4. 4.

    Shi L, Chen S, Zha X, Xu Y, Xu L, Yang L, et al. Enhancement of the TCRζ expression, polyclonal expansion and activation of T cells from patients with AML after IL-2, IL-7 and IL-12 induction. DNA Cell Biol. 2015 Mar 10. [Epub ahead of print]

  5. 5.

    Li Y. Alterations in the expression pattern of TCR zeta chain in T cells from patients with hematological diseases. Hematology. 2008;13:267–75.

  6. 6.

    Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol. 2000;111:817–25.

  7. 7.

    Chen S, Yang L, Chen S, Li Y. TCR ζ chain expression in T cells from patients with CML. Hematology. 2009;14:95–100.

  8. 8.

    Huang L, Chen S, Zha X, Yang L, Li B, Yu Z, et al. Expression feature of CD3, FcεRIγ and Zap-70 in patients with chronic lymphocytic leukemia. Hematology. 2012;17:71–5.

  9. 9.

    Zha X, Chen S, Yang L, Shi L, Li B, Wu X, et al. Up-regulated TCRζ enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol. 2012;31:1628–35.

  10. 10.

    Nambiar MP, Fisher CU, Warke VG, Krishnan S, Mitchell JP, Delaney N, et al. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48:1948–55.

  11. 11.

    Kaufman HL, Ruby CE, Hughes T, Slingluff Jr CL. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014;2:11.

  12. 12.

    Xuan L, Wu X, Zhang Y, Fan Z, Ling Y, Huang F, et al. Granulocyte colony-stimulating factor affects the distribution and clonality of TRGV and TRDV repertoire of T cells and graft-versus-host disease. J Transl Med. 2011;9:215.

Download references

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (Nos. 81100353, 81270604, and 81400109), the China Postdoctoral Science Foundation (No. 2013 M540685), the Guangdong Natural Science Foundation (Nos. S2013040016151 and S2013020012863), the Foundation for High-level Talents in Higher Education of Guangdong, China (No.[2013] 246-54), the Medical Science Foundation of Guangdong Province (Nos.A2011325 and B2013213), the Guangzhou Science and Technology Project foundation (201510010211), and the Fundamental Research Funds for the Central Universities (Nos. 21611447 and 21613313).

Author information

Correspondence to Yangqiu Li.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

YQL and SHC contributed to the concept development and study design. SHC, XFZ, LS, LLZ, LJY, BL, and XLW performed the experiments and analyzed the data. JZ, ZT, YHL, and KEZ were responsible for clinical diagnoses and performed clinical data acquisition. YQL, SHC, and XFZ coordinated the study and helped draft the manuscript. All authors read and approved the final manuscript.

Shaohua Chen and Xianfeng Zha contributed equally to this work.

Additional files

Additional file 1: Table S1.

Clinical data of AML patients.

Additional file 2:

Materials and methods.

Additional file 3: Figure S1.

Detection of the IFN-γ and TNF-α level in T cells from AML patients using Quantibody® array. A: Laser scanner fluorescence intensity (concentration) results. 1–4: samples from four cases with AML. B: The secretion level of IFN-γ and TNF-α in T cells from four cases with AML.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, S., Zha, X., Shi, L. et al. Upregulated TCRζ improves cytokine secretion in T cells from patients with AML. J Hematol Oncol 8, 72 (2015) doi:10.1186/s13045-015-0170-0

Download citation

Keywords

  • Acute myeloid leukemia
  • T cells
  • TCRζ
  • Cytokine
  • Chemokine